2016 American Transplant Congress
Subclinical Cytomegalovirus Viraemia in Renal Transplant Recipients.
Background: Studies suggest low-level cytomegalovirus (CMV) viraemia, detected with sensitive molecular assays, may lead to poorer graft outcomes following renal transplantation.Aims: Investigate the incidence, outcomes,…2016 American Transplant Congress
Clinical Predictors of Progression and Clearance of Low Level CMV Viremia in Solid Organ Transplant Recipients.
Multi-Organ Transplant Program, University Health Network, Toronto, ON, Canada.
Background: Low level CMV viremia is common, and may either progress to higher viral loads that require therapy, or may spontaneously resolve. The clinical predictors…2016 American Transplant Congress
Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVIg) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.
Houston Methodist Hospital, Houston, TX.
Ganciclovir resistant (GR) CMV is associated with an aggressive disease course and substantial morbidity. Furthermore, treatment options such as foscarnet and cidofovir are incredibly nephrotoxic.…2015 American Transplant Congress
Reciprocal Relationship Between Cytomegalovirus Infection and Graft Rejection in Intestinal/Multivisceral Transplantation: Impact on Survival and Ideal Immunosuppression Protocol
Transplant Surgery, Indiana University School of Medicine, Indianapolis, IN.
Background: Cytomegalovius (CMV) infection and graft rejection are opposing complications of isolated intestinal/multivisceral transplantation (IIT/MVT), a procedure requiring precise balance of immunosuppression. The aim of…2015 American Transplant Congress
Low Dose Valganciclovir Is an Effective Prophylaxis Against Cytomegalovirus in High Risk (Donor+/ Recipient-) Kidney Transplants Recipients
Introduction: Universal prophylaxis against Cytomegalovirus (CMV) disease is endorsed in high risk seronegative kidney (K) transplant (TX) recipients of organs from seropositive donors (D+/R-) using…